- Luxna Biotech and BioSpring have initiated a new collaboration to advance an oligonucleotide therapeutic based on Luxna’s proprietary XNA amidite chemistry.
- BioSpring will support process development, analytical characterisation and clinical manufacturing as part of its CDMO services.
Luxna Biotech has expanded its partnership with BioSpring GmbH through a new project aimed at developing an oligonucleotide therapeutic for an undisclosed target. The collaboration builds on a recently announced agreement between the two companies and focuses on translating Luxna’s proprietary XNA amidite chemistry into clinical applications.
The announcement outlines that BioSpring, a contract development and manufacturing organisation specialising in oligonucleotide therapeutics, will contribute expertise in process development, analytical characterisation and clinical manufacturing. Luxna will lead the advancement of the therapeutic candidate as it progresses towards clinical readiness.
The partnership addresses the need for integrated support in developing and scaling complex oligonucleotide programmes. BioSpring’s involvement is intended to accelerate the transition from early concept to clinic while ensuring reliable supply for future clinical and commercial requirements.
“This project marks the next step in translating Luxna’s XNA technology into therapeutic development,” said Hideaki Sato, President and CEO of Luxna Biotech.
Dr Sylvia Wojczewski, CEO of BioSpring, said the technology presents opportunities for innovation in the oligonucleotide field and noted BioSpring’s role in supporting Luxna’s therapeutic programmes.
